The study found that 3.6 million people (14.2% of Medicare beneficiaries) were highly likely to be eligible for Wegovy coverage if Medicare used a more conservative definition of established cardiovascular disease, and up to 15.2 million people (60.9% of beneficiaries) could be eligible if Medicare went with a more liberal definition
BPC-157 focuses on GH receptor and NO signaling
Injections are subcutaneous (under the skin), typically into the abdomen, thigh, or upper arm, and injection sites should be rotated weekly to prevent tissue buildup at any one spot
The FDA has confirmed it was not withdrawn due to safety or effectiveness issues
Any decision about whether to proceed belongs to the prescribing clinician
In future work, further studies on LALPVYN are still needed, with the aim of clarifying whether LALPVYN also possesses the same antioxidant activity in mice as in previous studies